Literature DB >> 33585332

Hypercalcaemia, Renal Dysfunction, Anaemia, Bone Disease (CRAB Criteria): A Case of Lymphoma.

Balraj Singh1, Pooja Gogia2, Parminder Kaur3, Nirmal Guragai3, Michael Maroules1.   

Abstract

Calcium elevation, Renal dysfunction, Anaemia and Bone disease (CRAB criteria) are usually seen in multiple myeloma (MM). We report a unique case of lymphoma with all the features of CRAB criteria. We describe a 59-year-old patient who presented with confusion, severe back pain, fatigue and constipation and was found to have hypercalcaemia, kidney dysfunction, anaemia and multiple osteolytic lesions. Physical examination and imaging did not reveal any enlarged lymph nodes. Work-up for MM (serum protein electrophoresis, serum immunofixation, bone marrow biopsy) was negative. The patient was diagnosed with diffuse large B-cell lymphoma based on a pelvic mass biopsy. Hence, our case report suggests that CRAB criteria are not pathognomonic of MM and that in the appropriate clinical scenario, lymphoma is a possible diagnosis. LEARNING POINTS: The CRAB criteria consist of end-organ damage with hypercalcaemia, renal dysfunction, anaemia and bone involvement.The CRAB criteria are not pathognomonic of multiple myeloma, and in the appropriate clinical scenario, lymphoma is a possible diagnosis.Major mechanisms by which hypercalcaemia of malignancy can occur are tumour secretion of parathyroid hormone-related protein (PTHrP), osteolytic metastases with local release of cytokines, or tumour production of 1,25-dihydroxyvitamin D (calcitriol). © EFIM 2020.

Entities:  

Keywords:  Hypercalcemia; anemia; lymphoma; multiple myeloma; osteolytic lesions

Year:  2020        PMID: 33585332      PMCID: PMC7875599          DOI: 10.12890/2020_002140

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  13 in total

Review 1.  Skeletal complications in cancer patients with bone metastases.

Authors:  Shunsuke Tsuzuki; Sun Hee Park; Matthew R Eber; Christopher M Peters; Yusuke Shiozawa
Journal:  Int J Urol       Date:  2016-08-03       Impact factor: 3.369

Review 2.  Multiple myeloma: Every year a new standard?

Authors:  S Vincent Rajkumar
Journal:  Hematol Oncol       Date:  2019-06       Impact factor: 5.271

Review 3.  Cancer-Related Hypercalcemia.

Authors:  Whitney Goldner
Journal:  J Oncol Pract       Date:  2016-05       Impact factor: 3.840

Review 4.  Anemia in cancer.

Authors:  M Dicato; L Plawny; M Diederich
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

5.  Prevalence and aetiology of anaemia in lymphoid malignancies.

Authors:  J Ghosh; R K Bikramjit Singh; R Saxena; R Gupta; S Vivekanandan; V Sreenivas; V Raina; A Sharma; L Kumar
Journal:  Natl Med J India       Date:  2013 Mar-Apr       Impact factor: 0.537

6.  Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) do not always represent multiple myeloma: diffuse large B cell lymphoma presenting with CRAB symptoms in a 69-year-old man.

Authors:  Hafez Mohammad Ammar Abdullah; Moataz Ellithi; Qazi Waqas; Arwyn Cunningham; Tony Oliver
Journal:  BMJ Case Rep       Date:  2019-08-04

Review 7.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

8.  Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.

Authors:  A J Greenberg; S V Rajkumar; T M Therneau; P P Singh; A Dispenzieri; S K Kumar
Journal:  Leukemia       Date:  2013-09-05       Impact factor: 11.528

Review 9.  Acute kidney injury in the patient with cancer.

Authors:  Mitchell H Rosner; Mark A Perazella
Journal:  Kidney Res Clin Pract       Date:  2019-09-30

10.  Hypercalcemia in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: An Unusual Presentation of a Rare Disease and Literature Review.

Authors:  Gabriella A Conte; Jonathan S Harmon; Marjolein L Le; Xiu Sun; Jake W Schuler; Michael J Levitt; Angelo A Chinnici; Mohammad A Hossain
Journal:  World J Oncol       Date:  2019-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.